Cash inflow regarding R&D spend

8 August 2011

TRISTEL plc

("Tristel" or the "Company ")

Cash inflow regarding R&D spend

Tristel plc (AIM : TSTL), the manufacturer of infection control, contamination control and hygiene products, announces it has received a corporation tax cash refund of £350,000 as a result of a retrospective research and development (R&D) tax claim. The funds received strengthen the Group's cash position.

As a consequence of the R&D tax relief the corporation tax accounts charge for the financial years 2010-11 and 2011-12 will be lower than previously anticipated, positively impacting earnings per share.

Appointment of Distributors

Following the Company's announcement in June that it has received regulatory approval for the Tristel Wipes System from the Therapeutic Goods Association (TGA), the body that regulates disinfectant use in Australia, Tristel is appointing two distributors to serve the Australian market. AshMed Pty Ltd will distribute the Wipes System into the urology and ear, nose and throat (ENT) markets. AshMed is also the distributor for Australia for Vision Science's revolutionary non-lumened cystoscopes. Scanmedics Pty Ltd will distribute the Wipes System into the hospital ultrasound market and is also the distributor for Australia for BK Medical's ultrasound products. Urology, ENT and ultrasound are key target markets for Tristel's Wipes System. Product sales have commenced in Australia.

For further information, please contact: